Drug General Information (ID: DDIXDOC1IQ)
Drug Name			Olaparib		Drug Info		Enfortumab vedotin		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Poly (Adp-Ribose) Polymerase Inhibitors				Antineoplastics

Mechanism of Olaparib-Enfortumab vedotin Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Olaparib				Enfortumab vedotin
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Olaparib and Enfortumab vedotin

Recommended Action
Management		Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.